Improve speech clarity with stimulation
- Trial ID
- NCT05182892
- Official Title
- REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis
- Goal
- Improve speech clarity with stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Study Type
- INTERVENTIONAL
- Enrollment
- 45 participants
- Conditions
- Parkinson Disease
- Interventions
- Change of stimulation amplitudes in dopaminergic OFF drug state
Plain-Language Summary
Aims to ease the speech worsening, called STN-DBS-induced dysarthria, that some people develop after subthalamic nucleus deep brain stimulation. The team adjusts the electrical stimulation amplitudes in the STN while you are off dopaminergic medication, using automated speech analysis to detect clearer speech so clinicians can find lower or different settings that improve clarity without losing motor benefit. Seeking adults 18+ with idiopathic Parkinson's who had bilateral STN-DBS at least three months ago, who notice worsening of speech tied to DBS, who are fluent in German or Swiss‑German, cognitively able to consent (MoCA >20), and with stable meds and DBS settings recently.
Locations
- Czech Technical University Prague, Prague, Czechia
- University Hospital Inselspital, Berne, Bern, Switzerland
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Change of stimulation amplitudes in dopaminergic OFF drug state. Aims to ease the speech worsening, called STN-DBS-induced dysarthria, that some people develop after subthalamic nucleus deep brain stimulation. The team adjusts the electrical stimulation amplitudes in the STN while you are off dopaminergic medication, using automated speech analysis to detect clearer speech so clinicians can find lower or different settings that improve clarity without losing motor benefit. Seeking adults 18+ with idiopathic Parkinson's who had bilateral STN-DBS at least three months ago, who notice worsening of speech tied to DBS, who are fluent in German or Swiss‑German, cognitively able to consent (MoCA >20), and with stable meds and DBS settings recently.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years.